Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-SLC37A4 Recombinant Antibody (7B9) (CBMAB-G6591-LY)


See all SLC37A4 antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human
Clone
7B9
Antibody Isotype
IgG
Application
WB

Basic Information

Specificity
Human
Antibody Isotype
IgG
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
solute carrier family 37 (glucose-6-phosphate transporter), member 4
Introduction
This gene regulates glucose-6-phosphate transport from the cytoplasm to the lumen of the endoplasmic reticulum, in order to maintain glucose homeostasis. It also plays a role in ATP-mediated calcium sequestration in the lumen of the endoplasmic reticulum. Mutations in this gene have been associated with various forms of glycogen storage disease. Alternative splicing in this gene results in multiple transcript variants.[provided by RefSeq, Aug 2009]
Entrez Gene ID
2542
UniProt ID
O43826
Alternative Names
Solute Carrier Family 37 Member 4; Solute Carrier Family 37 (Glucose-6-Phosphate Transporter); Member 4; Glucose-6-Phosphatase; Transport (Glucose-6-Phosphate) Protein 1; Transformation-Related Gene 19 Protein; Glucose-5-Phosphate Transporter; Glucose-6-Phosphate Translocase; TRG-19; G6PT1; Glucose-6-Phosphatase; Transport (Phosphate/Pyrophosphate) Protein 2; Glucose-6-Phosphatase; Transport (Glucose) Protein 3; Microsomal Glucose-6-Phosphate Transporter;
Function
Inorganic phosphate and glucose-6-phosphate antiporter of the endoplasmic reticulum. Transports cytoplasmic glucose-6-phosphate into the lumen of the endoplasmic reticulum and translocates inorganic phosphate into the opposite direction (PubMed:33964207).
Forms with glucose-6-phosphatase the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it plays a central role in homeostatic regulation of blood glucose levels.
Biological Process
Biological Process carbohydrate transportIEA:UniProtKB-KW
Biological Process gluconeogenesisTAS:Reactome
Biological Process glucose homeostasisIDA:UniProtKB
Biological Process glucose metabolic process1 PublicationNAS:UniProtKB
Biological Process glucose-6-phosphate transportManual Assertion Based On ExperimentIDA:UniProtKB
Biological Process phosphate ion transmembrane transportManual Assertion Based On ExperimentIDA:UniProtKB
Cellular Location
Endoplasmic reticulum membrane
Involvement in disease
Glycogen storage disease 1B (GSD1B):
A metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. Patients manifest a wide range of clinical symptoms and biochemical abnormalities, including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia. Glycogen storage disease type 1B patients also present a tendency towards infections associated with neutropenia, relapsing aphthous gingivostomatitis, and inflammatory bowel disease.
Glycogen storage disease 1C (GSD1C):
A metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. Patients manifest a wide range of clinical symptoms and biochemical abnormalities, including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia.
Glycogen storage disease 1D (GSD1D):
A metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. Patients manifest a wide range of clinical symptoms and biochemical abnormalities, including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia.
Congenital disorder of glycosylation 2W (CDG2W):
A form of congenital disorder of glycosylation, a genetically heterogeneous group of multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG2W is an autosomal dominant disorder characterized by liver dysfunction and coagulation deficiencies.
More Infomation
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-SLC37A4 Recombinant Antibody (7B9)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry